UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000032404 |
|---|---|
| Receipt number | R000036955 |
| Scientific Title | Verification test of body fat-reducing effect of lactic acid bacterium containing foods |
| Date of disclosure of the study information | 2018/05/21 |
| Last modified on | 2018/10/29 12:29:30 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Verification test of body fat-reducing effect of lactic acid bacterium containing foods
Acronym
Verification test of body fat-reducing effect of lactic acid bacterium containing foods
Scientific Title
Verification test of body fat-reducing effect of lactic acid bacterium containing foods
Scientific Title:Acronym
Verification test of body fat-reducing effect of lactic acid bacterium containing foods
Region
| Japan |
Condition
Condition
Healthy adult
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The objective of this study is to verify the effects on body fat of test foods in men and women aged 30 years and older and under 65 years of BMI23 and under 30
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Visceral fat area, body composition (body weight, body mass index, body fat percentage), and abdominal circumference
Key secondary outcomes
Hematologic test, blood biochemical test, vital signs
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Ingestion of test food containing a lactic acid bacterium for 12 consecutive weeks
Interventions/Control_2
Ingestion of placebo without a lactic acid bacterium for 12 consecutive weeks
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 30 | years-old | <= |
Age-upper limit
| 65 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1)Age: 30 and over, below 45
2)Sex: Males and females with Japanese nationality
3)Individuals with a BMI of 23 or more and less than 30 at screening (high-normal and 1st-degree obesity)
Key exclusion criteria
1)People who regularly drink or drink yogurt containing lactobacilli *Yogurt consumption will not be excluded if habit exists during the study
2)Persons who are unable to limit the use of drugs, health foods, foods for specified health use, functional labeling foods, health supplements, supplements, etc., which may affect body fat, as well as foods high in lactobacilli and oligosaccharides after obtaining informed consent
3)Subjects who were receiving medication at the time of study entry and were attending the clinic for body fat-related disease
4)Persons with or with a history of diseases such as diabetes, liver disease, kidney disease, or heart disease
5)Persons who have been diagnosed with familial hyperlipidemia
6)Persons currently undergoing exercise and diet therapy under the supervision of a physician
7)Persons who regularly engage in strenuous exercise
8)Persons with diseases requiring constant medication
9)Persons with a history of serious disease requiring medical treatment
10)Persons with a history of drug or food allergy
11)Patients who have metal in the CT scan measurement site due to surgery, etc.
12)Patients with cardiac pacemakers or implantable cardioverter defibrillators.
13)People with claustrophobia
14)Subjects who are judged inappropriate as subjects based on the responses to the background questionnaire
15)Subjects with significant deviations from reference ranges in pre-test physical, physical, and laboratory measurements
16)Pregnant, lactating women, or women who wish to become pregnant during the study
17)Persons with a current or past history of psychiatric disorders
18)Persons who work shift,such as night shift workers
19)Patients who are receiving or have a history of drug dependence or drug abuse.
20)Individuals who have participated in other human clinical studies or are currently participating in other human clinical studies within the past 3months
21)Other subjects who are considered inappropriate as subjects
22)Meetings are required
Target sample size
60
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Ochitani Daisuke |
Organization
HUMA R&D CORP
Division name
Clinical Development Division
Zip code
Address
Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan
TEL
81-3-3431-1260
ochitani@huma-c.co.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Ochitani Daisuke |
Organization
HUMA R&D CORP
Division name
Clinical Development Division
Zip code
Address
Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan
TEL
81-3-3431-1260
Homepage URL
ochitani@huma-c.co.jp
Sponsor or person
Institute
HUMA R&D CORP
Institute
Department
Personal name
Funding Source
Organization
Pickles corporation
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2018 | Year | 05 | Month | 21 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2018 | Year | 04 | Month | 13 | Day |
Date of IRB
Anticipated trial start date
| 2018 | Year | 05 | Month | 21 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2018 | Year | 04 | Month | 27 | Day |
Last modified on
| 2018 | Year | 10 | Month | 29 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036955
